Evaluation of effect on inflammation and oxidative stress of Citrate Dialysis fluid with central delivery system for maintenance hemodialysis patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0002273

Enrollment

Registered

2017-03-21

Start date

2016-10-03

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : A group : for 12 weeks citrate dialysate -&gt

for 12 weeks acetate dialysate B group : for 12 weeks acetate dialysate -&gt

for 12 weeks citrate dialysate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients aged 20-80 years (2) Patients on dialysis with end-stage renal failure (3) Patients on stable maintence dialysis for 6 months (4) Outpatient (5) A person who has signed a written agreement

Exclusion criteria

Exclusion criteria: (1) Those who have allergies to Citrate or had a history of adverse reactions (2) Those who received significant surgical and medical treatment within 3 months of participating in the study (3) Patients with liver dysfunction (AST, ALT> 3 times the upper limit of normal) (4) Current cancer patients with malignant tumors or patients who have not been diagnosed with cure (5) Prevalence of serious infectious diseases (6) Pregnant and lactating women (7) Those participating in the clinical trials currently under research and development (8) Other patients who were judged to be inadequate by the tester

Design outcomes

Primary

Measure	Time frame
Uremic toxin;Inflammatory Cytokine; Oxidative mediator	—

Countries

Korea, Republic of

Contacts

Public ContactKyung hwan Jeong

Kyung Hee University Hospital

aprilhwan@naver.com+82-2-958-8200

Outcome results